VEA
AUPH icon

Virtus ETF Advisers’s Aurinia Pharmaceuticals AUPH Stock Holding History

Virtus ETF Advisers’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,084
Closed -$324K – 456
2024
Q4 		$324K Sell
36,084
-25,477
-41% -$208K 0.13% 235
2024
Q3 		$451K Hold
61,561
– – 0.21% 188
2024
Q2 		$352K Buy
61,561
+19,366
+46% +$102K 0.17% 196
2024
Q1 		$211K Buy
42,195
+6,071
+17% +$41.2K 0.11% 244
2023
Q4 		$325K Buy
36,124
+5,267
+17% +$43.4K 0.21% 212
2023
Q3 		$240K Sell
30,857
-3,993
-11% -$39K 0.15% 228
2023
Q2 		$337K Sell
34,850
-31,098
-47% -$323K 0.2% 172
2023
Q1 		$723K Buy
65,948
+1,162
+2% +$10.2K 0.4% 122
2022
Q4 		$280K Buy
64,786
+39,866
+160% +$231K 0.15% 295
2022
Q3 		$187K Buy
24,920
+364
+1% +$3.15K 0.07% 325
2022
Q2 		$247K Buy
24,556
+3,903
+19% +$43.6K 0.09% 300
2022
Q1 		$256K Hold
20,653
– – 0.11% 184
2021
Q4 		$472K Buy
+20,653
New +$489K 0.18% 120

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtus ETF Advisers's AUPH Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2025, closing a stake of 36,084 shares — an estimated $324K sold.

Virtus ETF Advisers first reported a position in AUPH in Q4 2021 and held it in 13 quarters. The position peaked at $723K in Q1 2023. 214 funds tracked by Wall St. Rank hold AUPH as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Aurinia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 36,084 Aurinia Pharmaceuticals shares in Q1 2025, an estimated $324K.
  • Virtus ETF Advisers first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 13 quarters.
  • Virtus ETF Advisers's Aurinia Pharmaceuticals position peaked at $723K in Q1 2023.
  • 214 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.